Overview
PTHS market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
No longer tradingThis symbol is retired in our registry: it no longer trades, so it has no live decision and cannot be traded here.
- Last Close
- $9.47
- Last Trading Day
- 2026-10-30
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
- O
- 19.05
- H
- 19.05
- L
- 9.03
- C
- 9.47
- Vol
- 6,317.00
Daily history from Jan 15, 2026
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- stale
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $19.05
- Previous Close
- $16.12
- Day High
- $19.05
- Day Low
- $9.03
- 52 Week High
- $29.26
- 52 Week Low
- $9.03
- 7 Day Return
- -44.54%
- 30 Day Return
- -56.33%
- 90 Day Return
- -65.44%
- 1 Year Return
- —
- Daily Notional Volume
- $59.8K Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$23.04 Diluted earnings per share over the trailing twelve months.
- Beta
- 3.15 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -165.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $14.06 – $37.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $36M · P/S 0.83.